Reply  by Koksoy, Cuneyt
Regarding “A novel molecular mechanism to account
for the action of simvastatin against limb ischemia”
In the article by Koksoy and colleagues,1 the authors describe
that simvastatin markedly suppresses the functional activity of
neutrophils, which is underscored by reduced myeloperoxidase
activity compared with a placebo. I would like to add to the
discussion of Koksoy and coworkers1 by introducing a major route
through which simvastatin could suppress the activity of neutro-
phils.
The recent focus on ischemia-reperfusion injury has been
on interaction between neutrophils and endothelial cells. The
injury attributed to plugging of the microvasculature by neu-
trophils may initiate the cascade of injury by releasing free
radicals, enzymes, and cytokines, and physically injuring the
endothelium and obstructing the capillaries, thus, impairing
oxygen supply to the tissue. Also, transendothelial migration of
neutrophils, with release of reactive oxygen species and cyto-
kines, causes further damage to the injured tissue.2,3 However,
a key component in the pathogenesis of reperfusion syndrome is
the upregulation of surface adhesion molecules on the vascular
endothelium and their subsequent interaction with the acti-
vated neutrophils.4 The most important adhesion protein iden-
tified on neutrophils is the integrin lymphocyte function-asso-
ciated antigen-1 (LFA-1; CD11a/CD18), which is the ligand
for intercellular adhesion molecule-1 (ICAM-1) expressed on
the endothelium. The LFA-1/ICAM-1 interaction is crucial for
the ingress of neutrophils into the inflammatory sites.5,6 Simva-
statin downregulates the expression of ICAM-1 and LFA-1, and
through binding to LFA-1, it interferes with ICAM-1–LFA-1
interaction.7,8 This important mechanism should be borne in
mind as the major mechanism for simvastatin-induced inhibi-
tion of neutrophil activity.
Hamid Namazi, MD
Assistant Professor
Shiraz University of Medical Sciences
Chamran Hospital
Shiraz, Iran
REFERENCES
1. Köksoy C, Ozis¸ E, Cakmak A, YazganU,Okcu-Heper A, Köksoy A, et al.
Simvastatin pretreatment reduces the severity of limb ischemia in an
experimental diabetes model. J Vasc Surg 2007;45:590-6.
2. SiemionowM, Arslan E. Ischemia/reperfusion injury: a review in relation
to free tissue transfers. Microsurgery 2004;24:468-75.
3. Askar I, Oktay MF, Gurlek A, Bac B. Protective effects of some antineo-
plastic agents on ischemia-reperfusion injury in epigastric island skin
flaps. Microsurgery 2006;26:193-9.
4. Tosa Y, Lee WP, Kollias N, Randolph MA, May JW Jr. Monoclonal
antibody to intercellular adhesion molecule 1 protects skin flaps against
ischemia-reperfusion injury: an experimental study in rats. Plast Reconstr
Surg 1998;101:1586-94.
5. Haskard DO, Lee TH. The role of leukocyte-endothelial interactions in
the accumulation of leukocytes in allergic inflammation. Am Rev Respir
Dis 1992;145:10-3.
6. Chen PL, Easton A. Apoptotic Phenotype alters the capacity of tumor
necrosis factor-related apoptosis-inducing ligand to induce human vas-
cular endothelial activation. J Vasc Res 2007;45:111-22.
7. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-alpha-
induced apoptosis through the down-regulation of NF-kappaB-
dependent antiapoptotic gene products: role of IkappaBalpha kinase
and TGF-beta-activated kinase-1. J Immunol 2007;178:2507-16.
8. Pozo M, de Nicolas R, Egido J, Gonzalez-Cabrero J. Simvastatin inhibits
themigration and adhesion ofmonocytic cells and disorganizes the cytoskel-
eton of activated endothelial cells. Eur J Pharmacol 2006;548:53-63.
doi:10.1016/j.jvs.2008.01.063
Reply
Dr Namazi’s comments offer additional insight to our study.
Ischemia reperfusion injury provokes complex pathophysiologic
network involving distinct cell populations and humoral media-
tors. As pointed by the Dr Namazi, the most crucial step is
activation of the interaction between neutrophils and endothelial
cells. In our study, our primary purpose was to clarify the effects of
simvastatin pretreatment on the limb ischemia reperfusion injury in
an experimental diabetes model. Several techniques were used to
assess tissue injury including tissue myeloperoxidase (MPO) enzy-
matic activity as a measure of neutrophil infiltration. Statin pre-
treatment reduced the MPO activity compared with the untreated
groups. Unfortunately, we did not attempt to further define the
mechanisms for simvastatin induced inhibition of neutrophil activ-
ity. We agree with Dr Namazi who suggested that a key compo-
nent in the pathogenesis of reperfusion injury is upregulated
interaction between neutrophils and endothelial cells especially
LFA-1/ICAM-1 pathway.1,2 It has been shown that statins ame-
liorate tissue injury by concomitantly reducing expression of
LFA-1 and/or ICAM-1 in several ischemia reperfusion models
including the retina,3 brain, 4 and the bowel.5 Neutrophil adhesion
to the endothelium indicates a major component of ischemia/
reperfusion pathophysiology and may be a target for therapeutic
intervention.
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Regarding “Vascular abnormalities in patients with
neurofibromatosis syndrome type I: Clinical
spectrum, management, and results”
We read the article by Oderich et al1 and would like to add one
more case that we recently had who underwent a successful oper-
ation.
The patient is a 38-year old woman with neurofibromatosis
type I who has a history of bilateral renal and abdominal aortic
angioplasty, at the age of 10 and 2 years ago, for severe hyperten-
sion measuring 240/120.
The patient presented for vascular consultation on November
6, 2006, with recurrent hypertension and ischemic symptoms of
the lower extremities. Preoperative evaluation revealed suprarenal
stricture extending to the juxtarenal and infrarenal aorta with
bilateral renal artery stenoses. Rheumatology evaluation was essen-
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